Kamil. our everyone, you, for hand business afternoon, joining brief update today start it on you a time of our our call. our Thank Shanler, our clinical off us I Then Good plans programs. QX highlights to then thank will and development I'll and touch After review few Jeff and with commercial of our address Ruffo, Officer, a of business. then development our will CFO for which, Stuart lines. Interim Wayne, financial results. Frank review our who clinical Chief Head Scientific Commercial, will our will
force RHOFADE the questions. million. for of results will quarter particularly open be for remarks, were capacity your also earnings take trajectory when the prepared prescription the Following RHOFADE quarter the we pleased most our David our line during first were the the with at RHOFADE. the available of Gordon, Medical Starting first Today's up with Dr. our call. Chief full commercial. our highlights release portion to will Officer, very was about $X.X including revenues quarter. during net operating We XX% field relaunch, Q&A
from and in amongst according last over market any for to brand, months of and prescriptions particularly to field, rolling initial than the to first that team. a some the April new the rolling X,XXX dermatology since Xponent for turnover period medical strength were the you more XXth is been positive. the for force sales the we for the I As credit mid-December the more a believe focused commercial esthetically in that four-week reps. both I on which see very this is need with it the has report might trajectory the been Total detailed four our RHOFADE might expect, IQVIA physicians the has RHOFADE, am the feedback time importantly, anticipated of product, sales the focus pleased patients RHOFADE four-week data. ended period execution was
As is to our the goal reminder, back of monthly to TRX the rate by end of a get run a XX,XXX year.
earnings is sales our last to on in our position. which the on focus stated continue primary RHOFADE, and resources As call, efforts detail we
with in field remains only position focus ESKATA, productive the second Regarding for accounts. on a it now, detail
to few and to a turning pipeline our Now items note.
and We Phase have known development from safety treatment we clinical to for as an of alopecia exciting dermatitis candidates also as areata, atopic III male/female and of expect studies report busy also the us, studies the clinical milder multiple of II common results ahead efficacy year alopecia, treatment and and androgenetic severe our pattern warts. of baldness, and vitiligo for forms; both Phase the
options treatment alopecia As suffering the topical we from company a for reminder, both developing oral areata. are patients and only
address areata taken in and dermatology many mild, such the atopic disease. as the be following types case options appropriately have potential As dermatitis, typical approach. psoriasis for all with available moderate or severe disease other regimens of patients, and characterize it’d important patients whether is to it we is both indications treatment all the have To to alopecia fully severity,
topical disease allow spectrum severity of have a oral both enrollment designed studies of and to our patients broad trials. We our in with
have phase patients six an months. receive for We opportunity where provided also can treatment an trial to for they roll of open the additional topical extension an label oral into our
allowed an an We of of molecule ATI-XXX coming in this profile to This technology More look new treatment study. months We first also data drug to same the we drug extension enter generated application candidate the the from small to our an is be the submitted six-month the arthritis. consideration this sharing the important for investigational platform have and label forward open that in an the relative oral recently, up to versus for rheumatoid topical risk/benefit six we will maintain months. topical internally clinic. study the treatment through class in those remain additional on
approximately We in we expect single half we to patients a administrations the Phase into in successfully the inflammatory indications. ATI-XXX trial, to complete dose additional If II arthritis XX in rheumatoid in well as multiple patients I XXXX. as second begin expect trials trial, Phase including of with advance and
As candidate would These broad in production therapeutic If for established a and a advancement believe reminder, drugs. IL-X targets TNF ATI-XXX option generated This Aclaris. even is of inflammatory for IL-X. oral all IND new an investigational arthritis, a bowel psoriasis, of of that alpha, and cytokine disease we biologic suppurativa potential activity including of successful, to ATI-XXX be rheumatoid targets compound inflammatory the IL-X, ushers a era pyoderma oncology. first internally array drug hidradenitis indications, gangrenosum, CAPS our are
our generate and years, along we established clinical through development novel colleagues St. an and candidates team two stages which have preclinical Over allows in small drug into molecule internal us capability Louis, development. development the last drive and to of drug with and discovery later them the
programs. an candidate. institutional immunology our it update Chief is drugs ATI-XXX I Shanler, Our and and Stu? to chemistry first over provide Officer, combine space and clinical technology inhibitors, Stuart in Dr. in activities such efficiently inflammation develop will biology platform connect and expertise our new who on Scientific the to turn kinase to our other now will the our knowledge allow us
